

Caroline J Coats

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3931844/publications.pdf>

Version: 2024-02-01

24
papers

799
citations

623188

14
h-index

676716

22
g-index

24
all docs

24
docs citations

24
times ranked

1439
citing authors

#	ARTICLE	IF	CITATIONS
1	Calculated plasma volume status and prognosis in chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 35-43.	2.9	104
2	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2013, 34, 2529-2537.	1.0	84
3	Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2015, 8, 1022-1031.	1.6	79
4	Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease. <i>Heart</i> , 2015, 101, 961-966.	1.2	78
5	Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 1997-2002.	0.8	72
6	Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. <i>Europace</i> , 2011, 13, 1781-1788.	0.7	63
7	Role of Serum N-Terminal Pro-Brain Natriuretic Peptide Measurement in Diagnosis of Cardiac Involvement in Patients With Anderson-Fabry Disease. <i>American Journal of Cardiology</i> , 2013, 111, 111-117.	0.7	54
8	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001974.	1.6	38
9	Exercise-Induced Left Ventricular Outflow Tract Obstruction in Symptomatic Patients With Anderson-Fabry Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 88-89.	1.2	34
10	Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 114-127.	2.5	32
11	Arrhythmogenic Left Ventricular Cardiomyopathy. <i>Circulation</i> , 2009, 120, 2613-2614.	1.6	31
12	Pregnancy and its management in women with GSD type III – a single centre experience. <i>Journal of Inherited Metabolic Disease</i> , 2012, 35, 245-251.	1.7	25
13	Genetic biomarkers in hypertrophic cardiomyopathy. <i>Biomarkers in Medicine</i> , 2013, 7, 505-516.	0.6	24
14	Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 Mutations in Sporadic Hypertrophic Cardiomyopathy. <i>Circulation Journal</i> , 2013, 77, 2358-2365.	0.7	15
15	Peripartum cardiomyopathy: diagnosis and management. <i>Heart</i> , 2018, 104, 779-786.	1.2	14
16	Current applications of biomarkers in cardiomyopathies. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 825-837.	0.6	13
17	Familial dilated cardiomyopathy associated with pathogenic TBX5 variants: Expanding the cardiac phenotype associated with Holt-Oram syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 1725-1734.	0.7	12
18	Current management of hypertrophic cardiomyopathy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 496-504.	0.4	11

#	ARTICLE	IF	CITATIONS
19	Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK. <i>Advances in Therapy</i> , 2022, 39, 2292-2301.	1.3	11
20	The vital role of exercise testing in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 271, 200-201.	0.8	2
21	History of the British Cardiovascular Society. <i>Heart</i> , 2022, 108, 761-766.	1.2	2
22	The collapsing pulse. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, C78-C80.	0.2	1
23	Hypertrophic Cardiomyopathyâ€™Need for Gene-Specific Treatment?â€™Reply. <i>JAMA Cardiology</i> , 2019, 4, 831.	3.0	0
24	Arrhythmogenic Cardiomyopathyâ€™Further Insight into the Clinical Spectrum of Desmoplakin Disease. <i>Neurology International</i> , 2021, 11, 219-229.	0.2	0